



Eprosartan – Product discontinuation

- On March 16, 2020, the [FDA announced](#) the discontinuation of Mylan's [eprosartan](#) tablets due to business reasons.
 - Per Mylan, there is some product in stock with no further plans to manufacture additional product.
 - There are no other single ingredient formulations of eprosartan available.
 - The discontinuation is not due to product quality, safety, or efficacy issues.
- Eprosartan is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensives such as diuretics and calcium channel blockers.
- Other currently available ARBs include [candesartan](#), [irbesartan](#), [telmisartan](#), [losartan](#), [olmesartan](#), [valsartan](#). These are available as both brand and generics. Azilsartan is available only as brand [Edarbi](#)[™].
 - Refer to their respective drug labels for further indication information. These products are also available as combination products with other antihypertensives.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.